Information:
Fel:
ID
35757
Beskrivning
Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy; ODM derived from: https://clinicaltrials.gov/show/NCT02065791
Länk
https://clinicaltrials.gov/show/NCT02065791
Nyckelord
Versioner (1)
- 2019-03-20 2019-03-20 -
Rättsinnehavare
See clinicaltrials.gov
Uppladdad den
20 mars 2019
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Diabetes Mellitus, Type 2 NCT02065791
Eligibility Diabetes Mellitus, Type 2 NCT02065791
- StudyEvent: Eligibility
Similar models
Eligibility Diabetes Mellitus, Type 2 NCT02065791
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Diabetes Mellitus, Non-Insulin-Dependent | Hemoglobin A1c measurement | Estimated Glomerular Filtration Rate
Item
type 2 diabetes mellitus with a hemoglobin a1c (hba1c) greater than or equal to (>=) 6.5 percent (%) and less than or equal to (<=) 12.0%, with an estimated glomerular filtration rate (egfr) of >= 30 milliliter (ml)/minute (min)/1.73meter (m)^2 and less than (<) 90 ml/min/1.73 m^2
boolean
C0011860 (UMLS CUI [1])
C0474680 (UMLS CUI [2])
C3811844 (UMLS CUI [3])
C0474680 (UMLS CUI [2])
C3811844 (UMLS CUI [3])
Angiotensin-Converting Enzyme Inhibitors Maximum Tolerated Dose Stable Daily | Angiotensin II receptor antagonist Maximum Tolerated Dose Stable Daily
Item
participants need to be on a stable maximum tolerated labeled daily dose of an angiotensin-converting enzyme inhibitor (acei) or angiotensin receptor blocker (arb) for at least 4 weeks prior to randomization
boolean
C0003015 (UMLS CUI [1,1])
C0752079 (UMLS CUI [1,2])
C0205360 (UMLS CUI [1,3])
C0332173 (UMLS CUI [1,4])
C0521942 (UMLS CUI [2,1])
C0752079 (UMLS CUI [2,2])
C0205360 (UMLS CUI [2,3])
C0332173 (UMLS CUI [2,4])
C0752079 (UMLS CUI [1,2])
C0205360 (UMLS CUI [1,3])
C0332173 (UMLS CUI [1,4])
C0521942 (UMLS CUI [2,1])
C0752079 (UMLS CUI [2,2])
C0205360 (UMLS CUI [2,3])
C0332173 (UMLS CUI [2,4])
Urine albumin/creatinine ratio measurement
Item
must have a urine albumin to creatinine ratio (uacr) of greater than (>) 300 milligram (mg)/gram (g) and <= 5000 mg/g
boolean
C0455271 (UMLS CUI [1])
Diabetic Ketoacidosis | Diabetes Mellitus, Insulin-Dependent
Item
history of diabetic ketoacidosis or type 1 diabetes mellitus
boolean
C0011880 (UMLS CUI [1])
C0011854 (UMLS CUI [2])
C0011854 (UMLS CUI [2])
Glucose-galactose malabsorption Hereditary | Renal Glycosuria Primary
Item
history of hereditary glucose-galactose malabsorption or primary renal glucosuria
boolean
C0268186 (UMLS CUI [1,1])
C0439660 (UMLS CUI [1,2])
C0017980 (UMLS CUI [2,1])
C0205225 (UMLS CUI [2,2])
C0439660 (UMLS CUI [1,2])
C0017980 (UMLS CUI [2,1])
C0205225 (UMLS CUI [2,2])
Kidney Disease Requirement Therapeutic immunosuppression
Item
renal disease that required treatment with immunosuppressive therapy
boolean
C0022658 (UMLS CUI [1,1])
C1514873 (UMLS CUI [1,2])
C0021079 (UMLS CUI [1,3])
C1514873 (UMLS CUI [1,2])
C0021079 (UMLS CUI [1,3])
Liver disease
Item
known significant liver disease
boolean
C0023895 (UMLS CUI [1])
Heart failure New York Heart Association Classification
Item
current or history of new york heart association (nyha) class iv heart failure
boolean
C0018801 (UMLS CUI [1,1])
C1275491 (UMLS CUI [1,2])
C1275491 (UMLS CUI [1,2])
Blood potassium measurement
Item
blood potassium level >5.5 millimole (mmol)/liter (l) during screening
boolean
C0729816 (UMLS CUI [1])